SUNNYVALE, California – (BUSINESS WIRE) – JSR Life Sciences, LLC announced today that they are increasing their European footprint with a newly expanded state-of-the-art facility that will become the main European operating location for its affiliated companies KBI Biofarma and Selexis SA. The two companies combined will occupy at 8,700 square meters Stellar 32 campus within the ZIPLO Geneva (Industrial Zone Plan-les-Ouates). KBI Biopharma’s expanded facilities will enable the Company to offer the manufacturing of clinical cGMP biological medicinal ingredients for European clients. Selexis’ new workspace will enable the Company to meet the increasing demand for highly specialized mammalian cell line development technologies and services. Together, the companies anticipate the creation of more than 250 new, highly technical jobs at the new facility.
JSR Life Sciences invests in co-located operations to help meet the needs of its client base in Europe. This arrangement will facilitate additional options for clients to increase efficiency to integrate SURE SelexistechnologyTM protein expression platform with KBI’s advanced process and analytical development tools.
“JSR Life Sciences is proud to have a best-in-class company focused on translating customer ideas into new biologies that improve the lives of patients around the world,” said Tim Lowery, President of JSR Life Sciences. “This strategic investment in our European operations creates new options by linking the core strengths of our affiliates, increasing efficiency and ultimately accelerating the ability of our customers to bring innovative life science products to market. In addition, KBI and Selexis will benefit from the broad biopharma industry base, advanced technical resources, and special educational offerings in the region. “
KBI Biopharma’s 5,600-square-meter biological bulk drug manufacturing facility is scheduled to be operational in mid-2022 and will create more than 200 technical positions in development, operations and quality assurance. From this facility, KBI will supply cGMP bulk drug ingredients to customers to meet clinical trial requirements. The expanded capabilities include two 2,000L single-use cGMP manufacturing suites with on-site process development and analytical testing laboratories. CGMP quality control testing for release and in-process testing will be carried out on-site at the new Geneva facility, while cGMP testing for medicinal substances and drug product stability will continue at the KBI Biopharma BVBA laboratory in Leuven, Belgium.
The Geneva Selexis footprint will increase by 200% and is scheduled to be operational in mid-2021. The new spaces will include laboratory, office, health / fitness and employee common rooms. During the expansion, Selexis has maintained its commitment to Corporate Social Responsibility (CSR) through investing in Minergie-certified buildings (a Swiss building standard intended for construction with above average quality, comfort and energy demands) with a 20% better energy balance. of Swiss recommendations for energy resources and conservation1. The floor plans support the unique technical requirements of Selexis cell line workflows, including whole-department segregation and a sophisticated monitoring system. In addition to the new standard cell line development suite, the new facility will also include two separate cell culture sequences to accommodate client-specific, quarantined cell lines or client-specific cell line spaces.
“This expansion is the cornerstone of our European growth strategy, which is built on Selexis ‘innovative cell line technology and KBI’s strong expertise in biologic manufacturing to meet the needs of our clients’ clinical trial requirements. This new facility allows us to increase engagement with a wider client base with whom we can partner more effectively because of our local presence, “said Dirk Lange, President and CEO of KBI Biopharma and CEO of Selexis SA. “As science advances, research and treatment becomes increasingly complex and sophisticated, and we are fully prepared to keep up with the needs of our clients by providing the latest life science discoveries and development technologies. In addition, by putting these operations together, the synergy for fast cell lines and process development as well as the introduction of manufacturing will be extraordinary, which we see as a real boon to our client base. “
The Stellar 32 facility remains at the center of a highly diversified industrial company in Geneva. It provides easy access for clients and employees, is located close to Highway A1, Geneva Airport, and public transportation including buses, trams and several rail lines. Its location will also provide easy access to three-star hotels as well as a restaurant and fitness center.
About JSR Life Sciences, LLC
JSR Life Sciences, LLC is committed to advancing human health worldwide as a strategic partner for companies that discover, develop and deliver products to treat disease and improve the quality of life for patients. Based in Sunnyvale, California, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices. The JSR Life Sciences family of companies includes Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
About KBI Biopharma, Inc.
KBI Biopharma is an award-winning biopharmaceutical contract services organization that provides fully integrated and accelerated drug development and biomanufacturing services to pharmaceutical and biotech companies worldwide. With each of our 300+ client partners, we’ve worked together to quickly personalize and accelerate their drug development program. Built on a foundation of world-class analytical capabilities, we provide efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), Geneva, Switzerland, and Leuven, Belgium. Further information is available at www.kbibiopharma.com.
About Selexis SA
Selexis SA, the JSR Life Sciences Company, is a global leader in the development of cell lines with best-in-class modular technology and highly specialized solutions enabling the life science industry to rapidly discover, develop and commercialize innovative pharmaceuticals and vaccines. Our global partners leverage Selexis technology to advance more than 130 medicinal products in clinical development and manufacturing of eight commercial products. As part of a comprehensive drug development process, the Company’s technology shortens development times and reduces production risks. Further information is available at www.selexis.com.
1 That “The Cantonese Regulatory Model in the Energy Sector” (MuKEn) is a “whole package” of model regulations for the energy law in the building sector that the regions have developed jointly based on their experience in implementing them.
Check out the original version on businesswire.com: https://www.businesswire.com/news/home/20201020005340/en/